Pöördumine

Christy’s Story Snapshot of Christy’s Case “I want to beat this. I have no idea Christy is a 46-year-old part-time certified public accountant what I am facing and that is scary (CPA), wife, and mother of two young children. She volunteers for me.” with her children’s school and is active in various social organizations in her free time. Cancer Type: Breast Cancer Christy was diagnosed with early-stage breast cancer. The diagnosis terrified her, and immediate thoughts were about the Christy’s Goals/Preferences: impact of the diagnosis on her family. The guideline Preserve quality of life recommendation for treatment is surgery, hormone treatment, and potentially radiation. Christy met with the breast surgeon but Guideline Treatment: did not have a good sense of her prognosis. Christy has a genetic Surgery, Hormone Treatment, and predisposition towards forming blood clots and was admitted to Radiation the hospital ICU on two separate occasions in the recent past. She was concerned about the blood clotting risk of hormone Christy’s Treatment Decision: treatment and potential side effects of radiation, including heart Surgery and Reduced Hormone damage. Therapy ROI: Christy wanted to see the data and was referred to 30% Savings in treatment cost MyCancerJourney (MCJ), a patient support platform where trained board-certified patient advocates provide patients with detailed information on the outcomes of other people like themselves who Contact an Expert received different treatments. Christy met with a patient advocate and was pleasantly surprised by how favorable her prognosis was. 901 South Christy and the advocate discussed her treatment goals and Mopac Expy. personal preferences and created a report to support a shared Bldg. 1, Ste. 300 decision with her doctors and family. Austin, TX 78746 Christy met with her surgeon and medical oncologist and elected p 512. 508. 9000 to receive surgery, a reduced dose of hormone therapy, and w www.mycancerjourney.com forego radiation. Christy and her family were confident in their e [email protected] decision and appreciative of her care team's support.  Guideline Guideline Treatment Cost after using MCJ Cost Difference % 5-Year Survival Patient Choice Survival $ 76,580 $ 54,700 $ (21,880) (30%) 97% 97% Medical Information Age 46 Sex Female Race/ Ethnicity White Comorbidity Score Mild Histology Lobular-Ductal T (Primary Tumor) T1 N (Regional Lymph Nodes) NO M (Distant Metastasis) M0 ER Positive HER 2 Negative PR Positive ***This case is based on an actual patient’s experience; names have been modified for confidentiality. © 2022 PotentiaMetrics, Inc. All rights reserved. MCJ SOFTWARE SUMMARY Outsmarting Cancer with Data MCJ is a unique artificial intelligence software platform that provides personalized and actionable treatment information that oncologists and patients can use to optimize the best treatment plan. MCJ analyzes the outcomes of over 20 million cancer patients and considers critical patient-specific factors including, age, sex, race, and the patient’s comorbidities. MCJ reduces the use of unnecessary treatments, which in turn saves payors an average of 42% on their first year cancer costs. Innovative and Expansive • Cloud-based program driven by A.I. • Provides five-year projected treatment outcomes with 96% probability (+/- 2%). • Produces rich analytics for 15 cancer types, encompassing roughly 85% of new cancer cases. • Utilizes the Cox proportional-hazards model to estimate the association between the survival time of patients and predictor variables displayed with Kaplan-Meier survival curves. Robust Data & Expertly Validated • MCJ’s outcomes registry includes detailed information from over 20 million real world cancer cases that were collected from over 500 hospitals, cancer treatment centers, ambulatory surgery centers, clinical laboratories, and physician and other outpatient offices. • Models validated by world-renowned experts at Erasmus Medical Center, Rotterdam, Netherlands. • In addition to statistical validation, the models have also been reviewed by surgical, medical, and radiation oncologists. Significant Savings • 55% of patients change their treatment course as a result of the MCJ program. • Annual returns on investment from 350%-1400%. • Participating clients experience on average a 42% reduction of first year cancer costs. • Increases member & citizen satisfaction. 1/3  STEP BY STEP PRODUCTION OF A PATIENT REPORT Patient Synopsis Cash Flow Visualization 69 year male who was diagnosed with stage-4 prostate cancer. The guideline recommendation for treatment is radiation, chemotherapy, and hormone therapy. Step 1: Enter patient data Step 2: Select treatments to analyze Step 3: MCJ program calculates 5-year survivabilites for treatments selected Step 4: Analyze potential treatment costs 2-Year 5-Year Cost Cost Treatment Cost Survival % Survival % Difference ($) Difference (%) Guideline: Radiation, Chemotherapy, $75,480 60% 31% - - and Hormone Therapy Chemotherapy and Hormone Therapy $62,405 68% 41% ($13,075) -83% Hormone Therapy $48,734 73% 47% ($26,746) -35% Chemotherapy $4,755 80% 60% ($70,725) -94% Palliative Care $6,000 77% 54% ($69,480) -92% 2/3  PATIENT SCENARIOS AND ASSOCIATED COST SAVINGS Breast Cancer 46 year old white female with mild comorbdity score, and Lobular-Ductal breast cancer (T1, N0, M0, tumor markers ER and PR are positive, and tumor marker HER2 is negative) 2-Year 5-Year Cost Cost Treatment Cost Survival % Survival % Difference ($) Difference (%) Guideline: Surgery, Radiation $76,580 99% 97% - - and Hormone Therapy Surgery & Hormone Therapy $54,700 99% 97% ($21,880) -30% Surgery $13,128 99% 97% ($63,452) -83% Colon Cancer 57 year old white male with mild comorbidity score, and Carcinoma in his colon (T1, N0, M0) 2-Year 5-Year Cost Cost Treatment Cost Survival % Survival % Difference ($) Difference (%) Guideline: Surgery and Chemotherapy $61,500 95% 91% - - Surgery $17,427 94% 89% ($44,073) -72% Head and Neck Cancer 60 year old white male with moderate comorbidity score, and Squamous Cell Carcinoma cancer in his larynx (T2, N0, M0, HPV is negative) 2-Year 5-Year Cost Cost Treatment Cost Survival % Survival % Difference ($) Difference (%) Guideline: Surgery, Radiation, $133,616 82% 70% - - and Chemotherapy Chemotherapy $75,133 69% 51% ($58,483) -44% Radiation $20,158 79% 65% ($113,458) -85% Surgery and Radiation $38,483 86% 76% ($95,133) -72% Lung Cancer 49 year old white female with no comorbidities, and Non-Small Cell cancer in her lung (T3, N0, M0) 2-Year 5-Year Cost Cost Treatment Cost Survival % Survival % Difference ($) Difference (%) Guideline: Surgery, Chemotherapy, $141,663 72% 58% - - Radiation, and Immunotherapy Surgery $29,125 79% 68% ($112,538) -79% Surgery, Chemotherapy, Immunotherapy $105,817 79% 67% ($35,846) -25% Surgery, Chemotherapy, Radiation $136,663 76% 63% ($5,000) -4% 3/3 • • • • • • • • • • • • • • • Saatja: Sergei Oleshkevich <[email protected]> Saadetud: 16.03.2023 18:07 Adressaat: <"SM Info"> Koopia: Mark Morris <[email protected]> Teema: Att. Minister of Health and Labor for Estonia Mr. Peep Peterson Gentlemen, Please pass on the information from our mail to Mr. Peep Peterson, Minister of Health and Labor for Estonia. Thank you. Best regards, Sergei Oleshkevich Vice President of Eurasia Operations and Sales Morris Global Group, Ltd. morrisglobalgroup.com [email protected] Department of Public Health Direct dial + 31 10 703 00 45 Fax number +31 10 703 84 75 Internal postal address Na- 2324k E-mail [email protected] Our reference 0063SaR15ES Date June 03, 2015 Dear Dr. Piccirillo, Postal address P.O. box 2040 3000 CA Rotterdam, NL This is a report on the examination of the breast and prostate models that were recently developed by your group at Washington University, St Louis. At Erasmus MC, we studied Visiting address Wytemaweg 80 the proposed models according the current standards for development and validation of 3015 CN Rotterdam, NL prediction models, specifically the approaches outlined by Prof Harrell in his book ‘Regression Modeling Strategies’, and my book ‘Clinical Prediction Models’. Our team included Daan Car Park Wytemaweg 12 Nieboer (junior researcher), Yvonne Vergouwe, PhD (senior researcher), and myself. We all 3015 CN Rotterdam share an interest in prediction research for cancer patients. We found that the approach that you followed was generally well-supported and up to current standards for prognostication from observational registry data. Some minor issues were discussed by direct e-mail contact, such as the recoding of the age variable and reducing the number of interaction terms considered in the statistical model. Overall, we may expect that the proposed prediction models give accurate and valid estimates of survival for newly-diagnosed cancer. Sincerely, Ewout W. Steyerberg, PhD Professor of Medical Decision Making Richard’s Story Richard is a 60 year old physics professor who is actively teaching Snapshot of Richard’s Case and publishing research papers. In his free time, he is a gourmet cook and enjoys traveling with his family. Cancer Type: Head and Neck Cancer Richard was diagnosed with head and neck cancer. The guideline recommendation for treatment is surgery, radiation, and Richard’s Goals/Preferences: chemotherapy. Richard meets with the surgeon and learns that Preserve quality of life the surgery will remove his jaw, tongue, and larynx. Richard was hesitant to undergo this procedure. His medical oncologist and Guideline Treatment: radiation oncologist to discuss other treatment options. Surgery, Radiation and Chemotherapy As a physicist, Richard wanted to understand the probabilities and outcomes and also weigh the significant quality of life and Richard’s Treatment Decision: functioning tradeoffs associated with his treatment decision. A Radiation doctor friend refers him to MyCancerJourney (MCJ), a patient support platform where trained navigators provide patients with detailed information on the benefits and tradeoffs associated with their treatment options. Richard and his doctor were informed how this personalized information was developed using clinical outcomes of actual patients. MCJ provides the information Richard Contact an Expert requires to help make a difficult decision with more confidence. 901 South After seeing the data, and discussing the tradeoffs associated with Mopac Expy. treatment he elected to forgo surgery and chemotherapy and Bldg. 1, Ste. 300 received radiation treatment. Richards’ family and care team Austin, TX 78746 understood his goals and preferences and respected his selection. p 512. 508. 9000 w www.mycancerjourney.com e [email protected]  Guideline Patient Choice Guideline Treatment Cost after using MCJ Cost Difference % 5-Year Survival Survival $ 207,074 $ 20,158 $ (186,916) (90%) 52% 46% Medical Information Age 60 Sex Male Race/ Ethnicity White Comorbidity Score None Histology Squamous Cell Carcinoma Subsite Larynx T (Primary Tumor) T2 N (Regional Lymph N0 Nodes) M (Distant M0 Metastasis) HPV Negative ***This case is based on an actual patient’s experience; names have been modified for confidentiality. © 2022 PotentiaMetrics, Inc. All rights reserved. Mark G. Morris President and Chairman of the Board Morris Global Group Ltd. https://www.morrisglobalgroup.com/our-team#Morris www.morrisglobalgroup.com 1 602 770 8886 Peep Peterson Minister of Health and Labor for Estonia Suur-Ameerika 1, 10122 Tallinn, Estonia [email protected] Ph: +372 626 9301 March 14, 2023 Dear Sir, The Morris Global Group in the United States is honored to offer our innovative healthcare IT product to the Estonian Ministry of Health and Labor. Our product, the MCJ Software Program, utilizes the power of Artificial Intelligence to provide accurate, personalized, value-based and statistically reliable assessments of the consequences of various cancer treatment options. The utilization of the MCJ Software Program confidently results in improved patient survivability, quality of life and significant savings for the cancer treatment budget. Our Vice President of Eurasia Affairs, Mr. Sergei Oleshkevich, would be honored to introduce the MJC Software Program to the Ministry of Health and Labor for Estonia. The purpose is to demonstrate the significant cost benefits and quality of life impact the MCJ Software Program offers. During this demonstration, and upon mutual interest, Mr. Oleshkevich will be prepared to submit our formal offer to the Ministry of Health and Labor. For your information, I am attaching a presentation data for our product. Best Regards, Mark Morris Sergei Oleshkevich 1 623 276 7005 [email protected]